Advances in Therapy

, Volume 27, Issue 1, pp 1–16 | Cite as

Abacavir/lamivudine fixed-dose combination antiretroviral therapy for the treatment of HIV

  • Chad J. Achenbach
  • Kimberly K. Scarsi
  • Robert L. Murphy
Review

Abstract

In the past 15 years, improvements in the treatment of HIV infection have dramatically reduced morbidity and mortality. Nucleoside reverse transcriptase inhibitors are the backbone of combination antiretroviral therapy for the treatment of HIV. One of the recommended and commonly used therapies in this class is the once-daily fixed-dose combination of abacavir/lamivudine. Clinical studies and practice have shown these drugs to be potent, safe, and easy to use in a variety of settings; however, several recent reports have challenged the safety and efficacy claims among certain patient populations, including those at risk for cardiovascular disease and in those with high viral loads prior to treatment initiation. We reviewed abacavir/lamivudine as a treatment for HIV and discussed limitations of its use due to these controversial issues.

Keywords

abacavir antiretroviral therapy Epzicom HIV lamivudine nucleoside reverse transcriptase inhibitor 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Report on the Global AIDS Epidemic 2008. UNAIDS web site. Available at: www.unaids.org/en/KnowledgeCentre/HIVData/GlobalReport/2008/2008_Global_report.asp. Last accessed February 11, 2010.
  2. 2.
    Palella FJ Jr., Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338:853–860.CrossRefPubMedGoogle Scholar
  3. 3.
    Mocroft A, Ledergerber B, Katlama C, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet. 2003;362:22–29.CrossRefPubMedGoogle Scholar
  4. 4.
    Gazzard BG, Anderson J, Babiker A, et al. British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med. 2008;9:563–608.CrossRefPubMedGoogle Scholar
  5. 5.
    Hammer SM, Eron JJ Jr., Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA. 2008;300:555–570.CrossRefPubMedGoogle Scholar
  6. 6.
    Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services; December 1, 2009:1–161. Available at http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Last accessed: February 11, 2010.Google Scholar
  7. 7.
    Rapid advice: antiretroviral therapy for HIV infection in adults and adolescents. World Health Organization ART Guideline Review Committee; November 2009. Available at: www.who.int/hiv/pub/arv/rapid_advice_art.pdf. Last accessed: February 11, 2010.
  8. 8.
    Epzicom (package insert). Research Triangle Park, NC: GlaxoSmithKline; 2009.Google Scholar
  9. 9.
    Nolan D. HLA-B*5701 screening prior to abacavir prescription: clinical and laboratory aspects. Crit Rev Clin Lab Sci. 2009;46:153–165.CrossRefPubMedGoogle Scholar
  10. 10.
    Sabin CA, Worm SW, Weber R, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet. 2008;371:1417–1426.CrossRefPubMedGoogle Scholar
  11. 11.
    Lundgren JD, Neuhaus J, Babiker A, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS. 2008;22:F17–F24.CrossRefGoogle Scholar
  12. 12.
    Lang SM-KM, Cotte L, Gilquin L, et al. Impact of specific NRTI and PI exposure on the risk of myocardial infarction: a case-control study nested within FHDH ANRS C04. Abstract presented at: 16th Conference on Retroviruses and Oppotunistic Infections. February 8–11, 2009; Montreal, Canada. Abstract #43LB.Google Scholar
  13. 13.
    Obel N, Farkas D, Kronborg G, et al. Abacavir and risk of myocardial infarction in HIV-infected patients on highly active antiretroviral therapy: a population-based nationwide cohort study. HIV Med. 2010;11:130–136.CrossRefPubMedGoogle Scholar
  14. 14.
    Sax PE, Tierney C, Collier AC, et al. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. N Engl J Med. 2009;361:2230–2240.CrossRefPubMedGoogle Scholar
  15. 15.
    Baker KL, Lou Y, Yuen G, Murray S, Stein D. The bioequivalence and effect of food on a new once-a-day fixed-dose combination tablet of abacavir (ABC) and lamivudine (3TC). Poster presented at: 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. October 30, 2004–November 2, 2004; Washington, DC.Google Scholar
  16. 16.
    Chittick GE, Gillotin C, McDowell JA, et al. Abacavir: absolute bioavailability, bioequivalence of three oral formulations, and effect of food. Pharmacotherapy. 1999;19:932–942.CrossRefPubMedGoogle Scholar
  17. 17.
    Yuen GJ, Weller S, Pakes GE. A review of the pharmacokinetics of abacavir. Clin Pharmacokinet. 2008;47:351–371.CrossRefPubMedGoogle Scholar
  18. 18.
    Ziagen (package insert). Research Park Triangle, NC: GlaxoSmithKline; 2009.Google Scholar
  19. 19.
    Best BM, Mirochnick M, Capparelli EV, et al. Impact of pregnancy on abacavir pharmacokinetics. AIDS. 2006;20:553–560.CrossRefPubMedGoogle Scholar
  20. 20.
    Izzedine H, Launay-Vacher V, Aymard G, Legrand M, Deray G. Pharmacokinetics of abacavir in HIV-1-infected patients with impaired renal function. Nephron. 2001;89:62–67.CrossRefPubMedGoogle Scholar
  21. 21.
    Foster RH, Faulds D. Abacavir. Drugs. 1998;55:729–736; discussion 737-738.CrossRefPubMedGoogle Scholar
  22. 22.
    Moyle G, Boffito M, Fletcher C, et al. Steady-state pharmacokinetics of abacavir in plasma and intracellular carbovir triphosphate following administration of abacavir at 600 milligrams once daily and 300 milligrams twice daily in human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother. 2009;53:1532–1538.CrossRefPubMedGoogle Scholar
  23. 23.
    Hawkins T, Veikley W, St. Claire RL 3rd, Guyer B, Clark N, Kearney BP. Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens. J Acquir Immune Defic Syndr. 2005;39:406–411.CrossRefPubMedGoogle Scholar
  24. 24.
    Harris M, Back D, Kewn S, Jutha S, Marina R, Montaner JS. Intracellular carbovir triphosphate levels in patients taking abacavir once a day. AIDS. 2002;16:1196–1197.CrossRefPubMedGoogle Scholar
  25. 25.
    Piliero P, Shachoy-Clark AD, Para M, et al. A study examining the pharmacokinetics of abacavir and the intracellular carbovir triphosphate (GSK Protocol CNA 10905). Abstract presented at: 43rd International Conference on Antimicrobial Agents and Chemotherapy. September 14–17, 2003; Chicago, IL, USA. Abstract A-1797.Google Scholar
  26. 26.
    Weller S, Radomski KM, Lou Y, Stein DS. Population pharmacokinetics and pharmacodynamic modeling of abacavir (1592U89) from a dose-ranging, double-blind, randomized monotherapy trial with human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother. 2000;44:2052–2060.CrossRefPubMedGoogle Scholar
  27. 27.
    Moyle GJ, DeJesus E, Cahn P, et al. Abacavir once or twice daily combined with once-daily lamivudine and efavirenz for the treatment of antiretroviralnaive HIV-infected adults: results of the Ziagen Once Daily in Antiretroviral Combination Study. J Acquir Immune Defic Syndr. 2005;38:417–425.CrossRefPubMedGoogle Scholar
  28. 28.
    Goicoechea M, Jain S, Kemper C, et al., editors. Viral Dynamics and Pharmacokinetics in vivo of Tenofovir Disoproxil Fumarate and Abacavir: Evidence of a Non-additive Antiviral Effect. Poster presented at: 16th Conference on Retroviruses and Opportunistic Infections. February 8–11, 2009; Montréal, Canada. Poster no. 703.Available at: www.hivandhepatitis.com/2009icr/croi/pdf/3Golcoechea.pdf.
  29. 29.
    McDowell JA, Lou Y, Symonds WS, Stein DS. Multiple-dose pharmacokinetics and pharmacodynamics of abacavir alone and in combination with zidovudine in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother. 2000;44:2061–2067.CrossRefPubMedGoogle Scholar
  30. 30.
    Mastroianni CM, d’Ettorre G, Vullo V. Evolving simplified treatment strategies for HIV infection: the role of a single-class quadruple-nucleoside/nucleotide regimen of trizivir and tenofovir. Expert Opin Pharmacother. 2006;7:2233–2241.CrossRefPubMedGoogle Scholar
  31. 31.
    DiCenzo R, Forrest A, Squires KE, et al. Indinavir, efavirenz, and abacavir pharmacokinetics in human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother. 2003;47:1929–1935.CrossRefPubMedGoogle Scholar
  32. 32.
    Waters L, Moyle G, D’Avolio A, et al., editors. Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients. Antivir Ther. 2007;12:825–380.PubMedGoogle Scholar
  33. 33.
    Aptivus (package insert). Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc; 2009.Google Scholar
  34. 34.
    McDowell JA, Chittick GE, Stevens CP, Edwards KD, Stein DS. Pharmacokinetic interaction of abacavir (1592U89) and ethanol in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother. 2000;44:1686–1690.CrossRefPubMedGoogle Scholar
  35. 35.
    Bani-Sadr F, Denoeud L, Morand P, et al. Early virologic failure in HIV-coinfected hepatitis C patients treated with the peginterferon-ribavirin combination: does abacavir play a role? J Acquir Immune Defic Syndr. 2007;45:123–125.PubMedGoogle Scholar
  36. 36.
    Yuen GJ, Morris DM, Mydlow PK, Haidar S, Hall ST, Hussey EK. Pharmacokinetics, absolute bioavailability, and absorption characteristics of lamivudine. J Clin Pharmacol. 1995;35:1174–1180.PubMedGoogle Scholar
  37. 37.
    Epivir (package insert). Research Triangle Park, NC: GlaxoSmithKline; 2009.Google Scholar
  38. 38.
    Johnson MA, Moore KH, Yuen GJ, Bye A, Pakes GE. Clinical pharmacokinetics of lamivudine. Clin Pharmacokinet. 1999;36:41–66.CrossRefPubMedGoogle Scholar
  39. 39.
    Moodley J, Moodley D, Pillay K, et al. Pharmacokinetics and antiretroviral activity of lamivudine alone or when coadministered with zidovudine in human immunodeficiency virus type 1-infected pregnant women and their offspring. J Infect Dis. 1998;178:1327–1333.CrossRefPubMedGoogle Scholar
  40. 40.
    Heald AE, Hsyu PH, Yuen GJ, Robinson P, Mydlow P, Bartlett JA. Pharmacokinetics of lamivudine in human immunodeficiency virus-infected patients with renal dysfunction. Antimicrob Agents Chemother. 1996;40:1514–1519.PubMedGoogle Scholar
  41. 41.
    Johnson MA, Horak J, Breuel P. The pharmacokinetics of lamivudine in patients with impaired hepatic function. Eur J Clin Pharmacol. 1998;54:363–366.CrossRefPubMedGoogle Scholar
  42. 42.
    Moore KH, Yuen GJ, Raasch RH, et al. Pharmacokinetics of lamivudine administered alone and with trimethoprim-sulfamethoxazole. Clin Pharmacol Ther. 1996;59:550–558.CrossRefPubMedGoogle Scholar
  43. 43.
    Moore KH, Barrett JE, Shaw S, et al. The pharmacokinetics of lamivudine phosphorylation in peripheral blood mononuclear cells from patients infected with HIV-1. AIDS. 1999;13:2239–2250.CrossRefPubMedGoogle Scholar
  44. 44.
    Bruno R, Regazzi MB, Ciappina V, et al. Comparison of the plasma pharmacokinetics of lamivudine during twice and once daily administration in patients with HIV. Clin Pharmacokinet. 2001;40:695–700.CrossRefPubMedGoogle Scholar
  45. 45.
    Yuen GJ, Lou Y, Bumgarner NF, et al. Equivalent steady-state pharmacokinetics of lamivudine in plasma and lamivudine triphosphate within cells following administration of lamivudine at 300 milligrams once daily and 150 milligrams twice daily. Antimicrob Agents Chemother. 2004;48:176–182.CrossRefPubMedGoogle Scholar
  46. 46.
    DeJesus E, McCarty D, Farthing CF, et al. Once-daily versus twice-daily lamivudine, in combination with zidovudine and efavirenz, for the treatment of antiretroviral-naive adults with HIV infection: a randomized equivalence trial. Clin Infect Dis. 2004;39:411–418.CrossRefPubMedGoogle Scholar
  47. 47.
    Pruvost A, Negredo E, Theodoro F, et al. Pilot pharmacokinetic study of human immunodeficiency virus-infected patients receiving tenofovir disoproxil fumarate (TDF): investigation of systemic and intracellular interactions between TDF and abacavir, lamivudine, or lopinavir-ritonavir. Antimicrob Agents Chemother. 2009;53:1937–1943.CrossRefPubMedGoogle Scholar
  48. 48.
    Yuen GJ, Lou Y, Thompson NF, et al.et al. Abacavir/lamivudine/zidovudine as a combined formulation tablet: bioequivalence compared with each component administered concurrently and the effect of food on absorption. J Clin Pharmacol. 2001;41:277–288.CrossRefPubMedGoogle Scholar
  49. 49.
    Rodriguez-Torres M, Torriani FJ, Soriano V, et al. Effect of ribavirin on intracellular and plasma pharmacokinetics of nucleoside reverse transcriptase inhibitors in patients with human immunodeficiency virus-hepatitis C virus coinfection: results of a randomized clinical study. Antimicrob Agents Chemother. 2005;49:3997–4008.CrossRefPubMedGoogle Scholar
  50. 50.
    Cohen CJ, Kubota M, Brachman PS, et al. Shortterm safety and tolerability of a once-daily fixeddose abacavir-lamivudine combination versus twice-daily dosing of abacavir and lamivudine as separate components: findings from the ALOHA study. Pharmacotherapy. 2008;28:314–322.CrossRefPubMedGoogle Scholar
  51. 51.
    Goedken AM, Herman RA. Once-daily abacavir in place of twice-daily administration. Ann Pharmacother. 2005;39:1302–1308.CrossRefPubMedGoogle Scholar
  52. 52.
    Martinez E, Arranz JA, Podzamczer D, et al. A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir/lamivudine or tenofovir/emtricitabine in HIV-1-infected patients with virological suppression. J Acquir Immune Defic Syndr. 2009;51:290–297.CrossRefPubMedGoogle Scholar
  53. 53.
    Smith KY, Patel P, Fine D, et al. Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment. AIDS. 2009;23:1547–1556.CrossRefPubMedGoogle Scholar
  54. 54.
    Sosa N, Hill-Zabala C, Dejesus E, et al. Abacavir and lamivudine fixed-dose combination tablet once daily compared with abacavir and lamivudine twice daily in HIV-infected patients over 48 weeks (ESS30008, SEAL). J Acquir Immune Defic Syndr. 2005;40:422–427.CrossRefPubMedGoogle Scholar
  55. 55.
    Brothers CCA, Zhao H, Edwards M, Fleming J, Scott T. Once daily administration of abacavir is not a clinical risk factor for suspected hypersensitivity reactions in clinical trials and rash is not sufficient to diagnose the reaction. Poster presented at: 12th Conference on Retroviruses and Opportunistic Infections, Boston, USA. February 23, 2005. Poster 836.Google Scholar
  56. 56.
    Mallal S, Nolan D, Witt C, et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet. 2002;359:727–732.CrossRefPubMedGoogle Scholar
  57. 57.
    Hetherington S, Hughes AR, Mosteller M, et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet. 2002;359:1121–1122.CrossRefPubMedGoogle Scholar
  58. 58.
    Mallal S, Phillips E, Carosi G, et al. HLAB* 5701 screening for hypersensitivity to abacavir. N Engl J Med. 2008;358:568–579.CrossRefPubMedGoogle Scholar
  59. 59.
    Worm SW, Sabin C, Weber R, et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-hiv drugs (D:A:D) study. J Infect Dis. 2010;201:318–330.CrossRefPubMedGoogle Scholar
  60. 60.
    Calza L, Manfredi R, Colangeli V, et al. Efficacy and safety of atazanavir-ritonavir plus abacavir-lamivudine or tenofovir-emtricitabine in patients with hyperlipidaemia switched from a stable protease inhibitor-based regimen including one thymidine analogue. AIDS Patient Care STDS. 2009;23:691–697.CrossRefPubMedGoogle Scholar
  61. 61.
    Kumar PN, Rodriguez-French A, Thompson MA, et al. A prospective, 96-week study of the impact of Trizivir, Combivir/nelfinavir, and lamivudine/stavudine/nelfinavir on lipids, metabolic parameters and efficacy in antiretroviral-naive patients: effect of sex and ethnicity. HIV Med. 2006;7:85–98.CrossRefPubMedGoogle Scholar
  62. 62.
    Shikuma CM, Yang Y, Glesby MJ, et al. Metabolic effects of protease inhibitor-sparing antiretroviral regimens given as initial treatment of HIV-1 Infection (AIDS Clinical Trials Group Study A5095). J Acquir Immune Defic Syndr. 2007;44:540–550.CrossRefPubMedGoogle Scholar
  63. 63.
    Brothers CH, Hernandez JE, Cutrell AG, et al. Risk of myocardial infarction and abacavir therapy: no increased risk across 52 GlaxoSmithKline-sponsored clinical trials in adult subjects. J Acquir Immune Defic Syndr. 2009;51:20–28.CrossRefPubMedGoogle Scholar
  64. 64.
    Benson CRH, Zheng E, Koletar S, et al. No association of abacavir use with risk of myocardial infarction or severe cardiovascular disease events: results from ACTG A5001. Abstract presented at: 16th Conference on Retroviruses and Opportunistic Infections. February 8–11, 2009; Montreal, Canada. Abstract #721.Google Scholar
  65. 65.
    Durand MSO, Baril JA. Relation between use of nucleoside reverse transcriptase inhibitors (NRTI) and risk of myocardial infarction (MI): a nested case control study using Quebec’s public health insurance database (QPHID). Abstract presented at: 5th IAS Conference on HIV Pathogenesis, Treatment, and Prevention. July 19–22, 2009; Cape Town, South Africa. Abstract #TUPEB175.Google Scholar
  66. 66.
    Bedimo RWA, Dreschler H, Tebas P. Abacavir use and risk of acute myocardial infarction and cerebrovascular disease in the HAART era. Abstract presented at: 5th IAS Conference on HIV Pathogenesis, Treatment, and Prevention. July 19–22, 2009; Cape Town, South Africa. Abstract #MOAB202.Google Scholar
  67. 67.
    Post FA, Campbell LJ. Abacavir and increased risk of myocardial infarction. Lancet. 2008;372:803; author reply 4–5.CrossRefGoogle Scholar
  68. 68.
    Palella FGS, Elion R, Benning L, et al. Inflammatory markers among abacavir and non-abacavir recipients in the Womens’ Interagency HIV study and the Multicenter AIDS cohort study. Abstract presented at: 16th Conference on Retroviruses and Opportunistic Infections. February 8–11, 2009; Montreal, Canada. Abstract #150LB.Google Scholar
  69. 69.
    Martinez ELM, Perez I. No evidence for recent abacavir/lamivudine use in promoting inflammation, endothelial dysfunction, hypercoaguability, or insulin resistance in virologically suppressed HIV-infected patients: a substudy of the BICOMBO randomized clinical trial. 5th IAS Conference on HIV Pathogenesis, Treatment, and Prevention. July 19–22, 2009; Cape Town, South Africa. Abstract #MOAB203.Google Scholar
  70. 70.
    Hsue PY, Hunt PW, Wu Y, et al. Association of abacavir and impaired endothelial function in treated and suppressed HIV-infected patients. AIDS. 2009;23:2021–2027.CrossRefPubMedGoogle Scholar
  71. 71.
    Satchell C OCE, Peace A, Cotter A, Sheehan G, Tedesco T, Doran P, Powderly W, Kenny D, Mallon P. Platelet hyper-reactivity in HIV-1 infected patients on abacavir-containing ART. Abstract presented at: 15th Conference on Retroviruses and Opportunistic Infections. February 8–11, 2009; Montreal, Canada. Abstract #151LB.Google Scholar
  72. 72.
    DeJesus E, Herrera G, Teofilo E, et al. Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults. Clin Infect Dis. 2004;39:1038–1046.CrossRefPubMedGoogle Scholar
  73. 73.
    Lamarca A, Clumeck N, Plettenberg A, et al. Efficacy and safety of a once-daily fixed-dose combination of abacavir/lamivudine compared with abacavir twice daily and lamivudine once daily as separate entities in antiretroviral-experienced HIV-1-infected patients (CAL30001 Study). J Acquir Immune Defic Syndr. 2006;41:598–606.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Healthcare 2010

Authors and Affiliations

  • Chad J. Achenbach
    • 1
  • Kimberly K. Scarsi
    • 1
  • Robert L. Murphy
    • 1
  1. 1.Feinberg School of Medicine and Center for Global HealthNorthwestern UniversityChicagoUSA

Personalised recommendations